Analysis of Candidate miRNAs' Expression in Pancreatic Cancer

Rabeah Al‐Temaimi,Bicher Abdulkarim,Ali Al‐Ali,Bency John,Mrinmay Kumar Mallik,Kusum Kapila
DOI: https://doi.org/10.1002/cam4.70400
IF: 4.711
2024-11-10
Cancer Medicine
Abstract:miR‐196a‐5p upregulation in pancreatic cancer is associated with cancer progression. miR‐217‐5p is downregulated in pancreatic cancer allowing for KRAS overexpression. Background Pancreatic cancer (PC) is one of the most aggressive types of cancer. Despite advances in molecular diagnostics, PC diagnosis relies on imaging technologies and morphological assessment of fine needle aspirates (FNAs). MicroRNA (miRNA) involvement in PC pathogenesis and potential diagnostics application have been suggested, albeit current supporting evidence is lacking. Here, we investigated the association of selected miRNAs with PC incidence and clinical characteristics. Methods Fold expression of miR‐216a‐3p, ‐217‐5p, ‐221‐3p, ‐222‐3p, and miR‐196a‐5p was assessed in 73 PC FNA cell‐block sections and 6 healthy pancreas tissues using Taqman advanced miRNA assays. Potential miRNA targets were ascertained using immunocytochemistry. Results miR‐196a‐5p was upregulated in PC compared to healthy pancreatic tissue (β = −0.05, 95% CI: −0.065 – (−0.035); p
oncology
What problem does this paper attempt to address?